Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Net Income (2023 - 2025)

NewAmsterdam Pharma's Net Income history spans 3 years, with the latest figure at $71.1 million for Q4 2025.

  • For Q4 2025, Net Income rose 177.13% year-over-year to $71.1 million; the TTM value through Dec 2025 reached -$57.8 million, up 76.07%, while the annual FY2025 figure was -$57.8 million, 76.07% up from the prior year.
  • Net Income for Q4 2025 was $71.1 million at NewAmsterdam Pharma, up from -$72.0 million in the prior quarter.
  • Across five years, Net Income topped out at $71.1 million in Q4 2025 and bottomed at -$93.8 million in Q1 2024.
  • The 3-year median for Net Income is -$39.3 million (2024), against an average of -$33.9 million.
  • The largest annual shift saw Net Income tumbled 563.5% in 2024 before it soared 177.13% in 2025.
  • A 3-year view of Net Income shows it stood at $19.9 million in 2023, then crashed by 563.5% to -$92.2 million in 2024, then soared by 177.13% to $71.1 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Net Income are $71.1 million (Q4 2025), -$72.0 million (Q3 2025), and -$17.4 million (Q2 2025).